AU2002217927A1 - Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms - Google Patents

Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms

Info

Publication number: AU2002217927A1
Authority: AU; Australia
Prior art keywords: calcium; atorvastatin hemi; atorvastatin; hemi; suspension
Prior art date: 2000-11-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2002217927A

Other languages

English (en)

Inventor

Eti Ishai

Ramy Lidor-Hadas

Revital Lifshitz

Valerie Niddam

Guy Sambursky

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Teva Pharmaceutical Industries Ltd

Original Assignee

Teva Pharmaceutical Industries Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-30

Filing date

2001-11-29

Publication date

2002-06-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27540285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2002217927(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-11-29 Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd

2002-06-11 Publication of AU2002217927A1 publication Critical patent/AU2002217927A1/en

Status Abandoned legal-status Critical Current

Links

FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 title claims description 353
238000000034 method Methods 0.000 title claims description 88
230000008569 process Effects 0.000 title claims description 79
238000002360 preparation method Methods 0.000 title description 21
239000013078 crystal Substances 0.000 title description 13
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 177
239000000203 mixture Substances 0.000 claims description 78
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 78
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 62
239000000725 suspension Substances 0.000 claims description 52
239000007787 solid Substances 0.000 claims description 49
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 48
238000000634 powder X-ray diffraction Methods 0.000 claims description 42
239000012453 solvate Substances 0.000 claims description 37
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 34
150000004677 hydrates Chemical class 0.000 claims description 32
238000010992 reflux Methods 0.000 claims description 31
238000004519 manufacturing process Methods 0.000 claims description 29
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 23
229960005370 atorvastatin Drugs 0.000 claims description 23
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 21
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 21
239000002245 particle Substances 0.000 claims description 21
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 16
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 16
AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 16
239000000920 calcium hydroxide Substances 0.000 claims description 16
229910001861 calcium hydroxide Inorganic materials 0.000 claims description 16
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 16
239000000126 substance Substances 0.000 claims description 16
125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 14
238000006243 chemical reaction Methods 0.000 claims description 13
239000000499 gel Substances 0.000 claims description 13
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 12
150000002148 esters Chemical class 0.000 claims description 12
238000005481 NMR spectroscopy Methods 0.000 claims description 10
SWFBJYRYCRZMSB-KAYWLYCHSA-N Defluoroatorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 SWFBJYRYCRZMSB-KAYWLYCHSA-N 0.000 claims description 8
239000011575 calcium Substances 0.000 claims description 8
229910052791 calcium Inorganic materials 0.000 claims description 8
238000001035 drying Methods 0.000 claims description 8
238000009826 distribution Methods 0.000 claims description 7
239000002552 dosage form Substances 0.000 claims description 7
239000012296 anti-solvent Substances 0.000 claims description 6
-1 atorvastatin ester Chemical class 0.000 claims description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
230000001376 precipitating effect Effects 0.000 claims description 5
238000000655 nuclear magnetic resonance spectrum Methods 0.000 claims description 4
239000002253 acid Substances 0.000 claims description 3
238000000498 ball milling Methods 0.000 claims description 3
238000001816 cooling Methods 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
238000011084 recovery Methods 0.000 claims description 3
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 2
229910001424 calcium ion Inorganic materials 0.000 claims description 2
OUCSEDFVYPBLLF-KAYWLYCHSA-N 5-(4-fluorophenyl)-1-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-n,4-diphenyl-2-propan-2-ylpyrrole-3-carboxamide Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@H]2OC(=O)C[C@H](O)C2)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 OUCSEDFVYPBLLF-KAYWLYCHSA-N 0.000 claims 1
IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims 1
HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 claims 1
230000003381 solubilizing effect Effects 0.000 claims 1
150000004684 trihydrates Chemical group 0.000 claims 1
238000001914 filtration Methods 0.000 description 23
239000011541 reaction mixture Substances 0.000 description 17
239000000243 solution Substances 0.000 description 14
239000000463 material Substances 0.000 description 12
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
239000003814 drug Substances 0.000 description 10
230000005855 radiation Effects 0.000 description 10
229940079593 drug Drugs 0.000 description 9
239000000843 powder Substances 0.000 description 9
239000002002 slurry Substances 0.000 description 9
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 8
238000004458 analytical method Methods 0.000 description 8
229910052802 copper Inorganic materials 0.000 description 8
239000010949 copper Substances 0.000 description 8
238000001228 spectrum Methods 0.000 description 8
239000007858 starting material Substances 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
108010007622 LDL Lipoproteins Proteins 0.000 description 6
102000007330 LDL Lipoproteins Human genes 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
238000001144 powder X-ray diffraction data Methods 0.000 description 6
239000002244 precipitate Substances 0.000 description 6
239000003826 tablet Substances 0.000 description 6
235000012000 cholesterol Nutrition 0.000 description 5
238000004128 high performance liquid chromatography Methods 0.000 description 5
238000005259 measurement Methods 0.000 description 5
238000001556 precipitation Methods 0.000 description 5
239000002904 solvent Substances 0.000 description 5
229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 4
239000003085 diluting agent Substances 0.000 description 4
239000000706 filtrate Substances 0.000 description 4
229960004592 isopropanol Drugs 0.000 description 4
238000003801 milling Methods 0.000 description 4
230000000704 physical effect Effects 0.000 description 4
230000009467 reduction Effects 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
239000008247 solid mixture Substances 0.000 description 4
238000003756 stirring Methods 0.000 description 4
OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical group CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 description 3
102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 description 3
208000024172 Cardiovascular disease Diseases 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
108010046315 IDL Lipoproteins Proteins 0.000 description 3
125000001931 aliphatic group Chemical group 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
125000003118 aryl group Chemical group 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
235000010980 cellulose Nutrition 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
238000001944 continuous distillation Methods 0.000 description 3
238000004821 distillation Methods 0.000 description 3
150000002596 lactones Chemical group 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
238000005549 size reduction Methods 0.000 description 3
229910001220 stainless steel Inorganic materials 0.000 description 3
238000000341 synchrotron X-ray powder diffraction Methods 0.000 description 3
XUKUURHRXDUEBC-SVBPBHIXSA-N (3s,5s)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@H](O)C[C@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-SVBPBHIXSA-N 0.000 description 2
KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 2
102000000853 LDL receptors Human genes 0.000 description 2
108010001831 LDL receptors Proteins 0.000 description 2
229920000881 Modified starch Polymers 0.000 description 2
PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
238000009835 boiling Methods 0.000 description 2
238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000011109 contamination Methods 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
238000005384 cross polarization magic-angle spinning Methods 0.000 description 2
238000010908 decantation Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
239000002702 enteric coating Substances 0.000 description 2
238000009505 enteric coating Methods 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000011521 glass Substances 0.000 description 2
239000008187 granular material Substances 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
230000006872 improvement Effects 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
239000003921 oil Substances 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
239000000047 product Substances 0.000 description 2
238000000746 purification Methods 0.000 description 2
235000012239 silicon dioxide Nutrition 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
KJTLQQUUPVSXIM-ZCFIWIBFSA-M (R)-mevalonate Chemical compound OCC[C@](O)(C)CC([O-])=O KJTLQQUUPVSXIM-ZCFIWIBFSA-M 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 1
QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
ODYFGDACHPDINU-UHFFFAOYSA-N O.O.O.[Ca] Chemical compound O.O.O.[Ca] ODYFGDACHPDINU-UHFFFAOYSA-N 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930182558 Sterol Natural products 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
108010062497 VLDL Lipoproteins Proteins 0.000 description 1
238000002441 X-ray diffraction Methods 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000012615 aggregate Substances 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
238000010533 azeotropic distillation Methods 0.000 description 1
230000008901 benefit Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000012267 brine Substances 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
235000019821 dicalcium diphosphate Nutrition 0.000 description 1
229910000393 dicalcium diphosphate Inorganic materials 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
238000007908 dry granulation Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
125000004185 ester group Chemical group 0.000 description 1
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
230000009969 flowable effect Effects 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229960001031 glucose Drugs 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
125000001475 halogen functional group Chemical group 0.000 description 1
150000004679 hydroxides Chemical class 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000009878 intermolecular interaction Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000003902 lesion Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
229940002661 lipitor Drugs 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229920003145 methacrylic acid copolymer Polymers 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
239000001814 pectin Substances 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
229920003124 powdered cellulose Polymers 0.000 description 1
235000019814 powdered cellulose Nutrition 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000003825 pressing Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
239000010453 quartz Substances 0.000 description 1
238000009790 rate-determining step (RDS) Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
238000009738 saturating Methods 0.000 description 1
238000007873 sieving Methods 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
229960002855 simvastatin Drugs 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
159000000000 sodium salts Chemical group 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
229940045902 sodium stearyl fumarate Drugs 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
229940032147 starch Drugs 0.000 description 1
150000003432 sterols Chemical class 0.000 description 1
235000003702 sterols Nutrition 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000005846 sugar alcohols Chemical class 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
238000002411 thermogravimetry Methods 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
230000017105 transposition Effects 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
239000001993 wax Substances 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Epidemiology (AREA)
Pyrrole Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AU2002217927A 2000-11-30 2001-11-29 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms Abandoned AU2002217927A1 (en)

Applications Claiming Priority (11)

Application Number	Priority Date	Filing Date	Title
US25007200P	2000-11-30	2000-11-30
US60250072		2000-11-30
US26789701P	2001-02-09	2001-02-09
US60267897		2001-02-09
US28187201P	2001-04-05	2001-04-05
US60281872		2001-04-05
US31214401P	2001-08-13	2001-08-13
US60312144		2001-08-13
US32652901P	2001-10-01	2001-10-01
US60326529		2001-10-01
PCT/US2001/044636 WO2002043732A1 (fr)	2000-11-30	2001-11-29	Nouvelles formes cristallines d'hemi-calcium d'atorvastatine et leurs procedes de preparation, et nouveaux procedes de preparation d'autres formes

Publications (1)

Publication Number	Publication Date
AU2002217927A1 true AU2002217927A1 (en)	2002-06-11

Family

ID=27540285

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2002217927A Abandoned AU2002217927A1 (en)	2000-11-30	2001-11-29	Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms

Country Status (23)

Country	Link
US (15)	US20020183378A1 (fr)
EP (5)	EP2192112B1 (fr)
JP (2)	JP2004514694A (fr)
KR (1)	KR100765871B1 (fr)
CN (1)	CN1489463A (fr)
AU (1)	AU2002217927A1 (fr)
BG (1)	BG107856A (fr)
BR (1)	BR0115892A (fr)
CA (3)	CA2429590C (fr)
CZ (1)	CZ20031766A3 (fr)
DE (1)	DE01998348T1 (fr)
ES (2)	ES2437157T3 (fr)
HR (2)	HRP20130545A2 (fr)
HU (1)	HUP0600538A3 (fr)
IL (2)	IL156055A0 (fr)
IS (1)	IS6829A (fr)
MX (1)	MXPA03004844A (fr)
NO (1)	NO20032425L (fr)
PL (1)	PL363228A1 (fr)
SK (1)	SK8062003A3 (fr)
TR (1)	TR200400815T3 (fr)
WO (1)	WO2002043732A1 (fr)
YU (1)	YU42803A (fr)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
USRE36268E (en) *	1988-03-15	1999-08-17	Boehringer Mannheim Corporation	Method and apparatus for amperometric diagnostic analysis
US7411075B1 (en)	2000-11-16	2008-08-12	Teva Pharmaceutical Industries Ltd.	Polymorphic form of atorvastatin calcium
PL362472A1 (en) *	2000-11-03	2004-11-02	Teva Pharma	Atorvastatin hemi-calcium form vii
EP1341785B1 (fr) *	2000-11-16	2008-10-08	Teva Pharmaceutical Industries Ltd.	Hydrolyse d'esters d'acide r(r,r)-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- [(phenylamino)carbonyl]-1h-pyrrole-1-heptanoique au moyen d'hydroxyde de calcium
US7501450B2 (en)	2000-11-30	2009-03-10	Teva Pharaceutical Industries Ltd.	Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en)	2000-11-30	2003-12-23	Teva Pharma	Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7538136B2 (en) *	2000-12-27	2009-05-26	Teva Pharmaceutical Industries Ltd.	Crystalline forms of atorvastatin
KR100609371B1 (ko) *	2001-06-29	2006-08-08	워너-램버트 캄파니 엘엘씨	Ｒ-(ｒ,ｒ)-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-페닐아미노)카르보닐-1ｈ-피롤-1-헵탄산 칼슘염 (2:1) (아토르바스타틴)의 결정질 형태
US7074818B2 (en)	2001-07-30	2006-07-11	Dr. Reddy's Laboratories Limited	Crystalline forms VI and VII of Atorvastatin calcium
BR0211488A (pt) *	2001-07-30	2004-08-17	Reddys Lab Ltd Dr	Formas cristalinas vi e vii de atorvastina cálcica
JP4188826B2 (ja) *	2001-08-16	2008-12-03	テバファーマシューティカルインダストリーズリミティド	カルシウム塩型スタチンの製造方法
CZ296967B6 (cs) *	2002-02-01	2006-08-16	Zentiva, A.S.	Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
CN100406436C (zh) *	2002-02-15	2008-07-30	特瓦制药工业有限公司	阿托韦兹他汀半钙结晶以及制备阿托韦兹他汀半钙形式ix的方法
CA2475123A1 (fr)	2002-02-19	2003-08-28	Teva Pharmaceutical Industries Ltd.	Processus destines a la desolvation des solvates de demi-calcium d'atorvastatine et demi-calcium d'atorvastatine sensiblement exempt de solvant organique
AU2002356423A1 (en) *	2002-05-28	2003-12-12	Cadila Healthcare Limited	Process for the preparation of amorphous atorvastatin calcium
GB0218781D0 (en)	2002-08-13	2002-09-18	Astrazeneca Ab	Chemical process
AU2002330735A1 (en) *	2002-09-03	2004-03-29	Morepen Laboratories Limited	Atorvastatin calcium form vi or hydrates thereof
EP1424324A1 (fr) *	2002-11-28	2004-06-02	Teva Pharmaceutical Industries Limited	Forme cristalline F de calcium d'atorvastatine
EP1572643A2 (fr) *	2002-11-28	2005-09-14	Teva Pharmaceutical Industries Ltd.	Forme cristalline du sel hemi calcique de l'atorvastatine
JP4901474B2 (ja) *	2003-05-30	2012-03-21	ランバクシーラボラトリーズリミテッド	置換ピロール誘導体
GB0312896D0 (en)	2003-06-05	2003-07-09	Astrazeneca Ab	Chemical process
US7790197B2 (en)	2003-06-09	2010-09-07	Warner-Lambert Company Llc	Pharmaceutical compositions of atorvastatin
US7655692B2 (en)	2003-06-12	2010-02-02	Pfizer Inc.	Process for forming amorphous atorvastatin
US20050271717A1 (en)	2003-06-12	2005-12-08	Alfred Berchielli	Pharmaceutical compositions of atorvastatin
UY28501A1 (es)	2003-09-10	2005-04-29	Astrazeneca Uk Ltd	Compuestos químicos
GB0324791D0 (en)	2003-10-24	2003-11-26	Astrazeneca Ab	Chemical process
ITMI20032144A1 (it) *	2003-11-07	2005-05-08	Alfa Wassermann Spa	Forme polimorfe di rifaximina, processi per ottenerle e
CA2456430A1 (fr) *	2004-01-28	2005-07-28	Brantford Chemicals Inc.	Procede ameliore pour la preparation d'atorvastatine calcique amorphe
CA2666359A1 (fr)	2004-03-17	2005-10-06	Yatendra Kumar	Procede de production d'atorvastatine calcique sous forme amorphe
ES2739493T3 (es)	2004-05-05	2020-01-31	Pfizer Prod Inc	Formas de sal de de atorvastatina con benetamina
BRPI0511508A (pt) *	2004-05-24	2008-01-08	Warner Lambert Co	formas de sais de atorvastatina, composição farmacêutica e processo
CN1997651B (zh) *	2004-07-16	2012-06-06	力奇制药公司	阿托伐他汀钙的氧化降解产物
BRPI0513422A (pt)	2004-07-20	2008-05-06	Warner Lambert Co	formas de sais cálcio do ácido (r-(r*))-2-(4- fluorfenil)-(beta), (sigma)-diidróxi-5-(1-metiletil) -3-fenil-4-((fenilamino) carbonil)-1h-pirrol-1-heptanóico (2:1)
DE202005020766U1 (de) *	2004-07-22	2006-10-05	Teva Pharmaceutical Industries Ltd.	Neue Kristallformen von Atorvastatin-Hemi-Calcium
CA2579997A1 (fr) *	2004-09-28	2006-04-06	Teva Pharmaceutical Industries Ltd.	Procede de preparation de formes d'atorvastatine calcique sensiblement exemptes d'impuretes
EP1793815A4 (fr) *	2004-09-30	2010-12-29	Reddys Lab Ltd Dr	Atorvastatine calcique amorphe
TW200942516A (en) *	2004-10-18	2009-10-16	Teva Pharma	Processes for preparing amorphous atorvastatin hemi-calcium
AU2005298383A1 (en)	2004-10-28	2006-05-04	Warner-Lambert Company Llc	Process for forming amorphous atorvastatin
WO2006048894A1 (fr) *	2004-11-05	2006-05-11	Morepen Laboratories Limited	Nouvelles formes cristallines de calcium d'atorvastatine et procedes de fabrication
CA2588216A1 (fr) *	2004-11-22	2006-05-26	Dexcel Pharma Technologies Ltd.	Formulations d'atorvastatine stables
ES2522895T3 (es) *	2005-03-03	2014-11-19	Alfa Wassermann S.P.A.	Nuevas formas polimorfas de rifaximina, procedimientos para su producción y uso de las mismas en preparados medicinales
JP5523699B2 (ja) *	2005-04-08	2014-06-18	エギシュヂョヂセルヂャールニルヴァーノサンミケデレースヴェーニタールササーグ	新規な結晶性のアトルバスタチンヘミカルシウム塩の多形相
US20070032665A1 (en) *	2005-08-04	2007-02-08	Srinivasulu Gudipati	Preparation of atorvastatin calcium form i
ES2270722B1 (es) *	2005-09-15	2008-03-01	Ercros Industrial, S.A.	Procedimiento para la obtencion de atorvastatina calcica amorfa.
US20090216029A1 (en) *	2005-09-16	2009-08-27	Yatendra Kumar	Process for the production of atorvastatin calcium in amorphous form
CA2547216A1 (fr)	2005-09-21	2007-03-21	Renuka D. Reddy	Procede de recuit de l'atorvastatine amorphe
KR101329112B1 (ko)	2005-11-08	2013-11-14	랜박시 래보러터리스 리미티드	(3ｒ,5ｒ)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법
EP1923057A1 (fr)	2005-11-21	2008-05-21	Teva Pharmaceutical Industries Ltd	Formule pharmaceutique atorvastanine
ES2304335T3 (es)	2005-11-21	2010-05-19	Warner-Lambert Company Llc	Formas nuevas del acido (r-(r,r))-2-(4-fluorofenil)-b,b-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)1h-pirrol-1-heptanoico, de magnesio.
EP1808162A1 (fr)	2005-11-21	2007-07-18	Teva Pharmaceutical Industries Ltd.	Formulation pharmacéutique de l'Atorvastatin
CN101370774A (zh) *	2005-12-13	2009-02-18	特瓦制药工业有限公司	阿托伐他汀半钙的晶形及其制备方法
EP1810667A1 (fr)	2006-01-20	2007-07-25	KRKA, tovarna zdravil, d.d., Novo mesto	Composition pharmaceutique contenant de l'atorvastatin amorphé
JP2007246514A (ja) *	2006-02-14	2007-09-27	Toyama Chem Co Ltd	ピペラシリンナトリウムの新規な結晶
AU2007219107B2 (en) *	2006-02-22	2012-12-06	Mylan Laboratories Ltd.	New crystalline form of Atorvastatin hemi-calcium
JP2007231018A (ja) *	2006-03-01	2007-09-13	Teva Pharmaceutical Industries Ltd	アトルバスタチンヘミカルシウムの結晶形の調製方法
US20070265456A1 (en) *	2006-05-09	2007-11-15	Judith Aronhime	Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
CN100406438C (zh) *	2006-06-30	2008-07-30	浙江新东港药业股份有限公司	一种无定型阿伐他汀钙的制备方法
US20080153896A1 (en) *	2006-07-14	2008-06-26	Gyan Chand Yadav	Polymorphic Forms of an HMG-CoA Reductase Inhibitor and Uses Thereof
US20100029743A1 (en) *	2006-09-27	2010-02-04	Dr. Reddy's Laboratories Ltd.	Atorvastatin pharmaceutical compositions
US20100113802A1 (en) *	2006-11-02	2010-05-06	Cadila Pharmaceuticals Limited	Process for preparing amorphous atorvastatin hemi calcium salt and its itermediate
US7834195B2 (en) *	2007-01-24	2010-11-16	Apotex Pharmachem Inc.	Atorvastatin calcium propylene glycol solvates
CN101611040A (zh) *	2007-01-31	2009-12-23	富山化学工业株式会社	哌拉西林钠的新颖结晶
WO2008108572A1 (fr) *	2007-03-02	2008-09-12	Dong-A Pharm. Co., Ltd.	Nouvelles formes cristallines de dérivés d'acide pyrrolylheptanoïque
WO2008129562A2 (fr) *	2007-04-20	2008-10-30	Morepen Laboratories Limited	Procédé amélioré pour la préparation d'atorvastatine amorphe hémicalcique stable et de ses sels
AU2008281640A1 (en) *	2007-07-27	2009-02-05	Cipla Limited	Pharmaceutical compositions and process for making them
WO2009082362A1 (fr) *	2007-11-05	2009-07-02	Ulkar Kimya San. Ve Tic. A.S.	Procédé de procution de statines sous forme pure
EP2075246A1 (fr)	2007-12-27	2009-07-01	M. J. Institute of Research	Procédé de préparation de forme amorphe de sel hémicalcium atorvastanine
CN101538237B (zh) *	2008-05-30	2011-04-06	天津和美生物技术有限公司	阿伐他汀半钙盐丁酮共结晶物、其制备和作为HMG-CoA酶抑制剂的应用
JP2011528231A (ja)	2008-07-17	2011-11-17	デラヴァルホールディングエービー	食品および飲料の製造および取扱い設備の洗浄方法
WO2011028309A1 (fr)	2009-09-04	2011-03-10	University Of Toledo	Procédés de fabrication de bêta-lactones optiquement pures à partir d'aldéhydes et compositions obtenues par ces procédés
US11473032B2 (en)	2010-02-02	2022-10-18	Fuchs Petrolub Se	Constant velocity joint having a boot
IT1398550B1 (it)	2010-03-05	2013-03-01	Alfa Wassermann Spa	Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
KR20120011249A (ko)	2010-07-28	2012-02-07	주식회사 경보제약	아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
ITBO20120368A1 (it)	2012-07-06	2014-01-07	Alfa Wassermann Spa	Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
CN102766136A (zh) *	2012-08-07	2012-11-07	浙江宏元药业有限公司	一种制备阿托伐他汀钙中间体的方法
SG10202012791TA (en)	2013-11-15	2021-01-28	Akebia Therapeutics Inc	Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
CN105111123A (zh) *	2013-11-25	2015-12-02	李兴惠	阿托伐他汀钙及组合物
CN104945300B (zh) *	2015-06-17	2017-05-10	北京嘉林药业股份有限公司	一种ⅰ型阿托伐他汀钙的纯化方法
CN104983690A (zh) *	2015-08-18	2015-10-21	青岛蓝盛洋医药生物科技有限责任公司	一种治疗冠心病的药物阿托伐他汀钙组合物干混悬剂
EP3272336A1 (fr) *	2016-07-19	2018-01-24	Stada Arzneimittel Ag	Composition d'atorvastatine
WO2025147589A1 (fr)	2024-01-05	2025-07-10	Osanni Bio, Inc.	Implants, compositions et méthodes de traitement de maladies et de troubles de la rétine

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US115709A (en) *		1871-06-06		Improvement in curriers slickers
US99224A (en) *		1870-01-25		Improvement in pocket-sates for friction-matches
US2598627A (en) *	1949-10-11	1952-05-27	Robert Gair Co Inc	Folding carton
DE2748825C2 (de) *	1976-11-02	1986-11-27	Sankyo Co., Ltd., Tokio/Tokyo	Substituierte 3,5-Dihydroxyheptansäurederivate und diese enthaltende Arzneimittel gegen Hyperlipämie
US4681893A (en)	1986-05-30	1987-07-21	Warner-Lambert Company	Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) *	1988-02-22	1991-03-26	Warner-Lambert Company	Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
FI94339C (fi)	1989-07-21	1995-08-25	Warner Lambert Co	Menetelmä farmaseuttisesti käyttökelpoisen /R-(R,R)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
CA2150372C (fr) *	1993-01-19	2002-08-20	Nancy L. Mills	Composition orale stable de ci-981 et procede de preparation
US5298627A (en) *	1993-03-03	1994-03-29	Warner-Lambert Company	Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
DE4411536A1 (de) *	1994-04-02	1995-10-05	Cassella Ag	Wasserquellbare hydrophile Polymere
HRP960313B1 (en) *	1995-07-17	2002-08-31	Warner Lambert Co	Form iii crystalline (r- (r, r)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
EA000474B1 (ru) *	1995-07-17	1999-08-26	Варнер-Ламберт Компани	Кристаллическая кислая кальциевая соль [r-(r, r)]-2-(4-фторфенил)-бета, дельта-дигидрокси-5-(1-метилэтил)-3-фенил-4-[(фениламино)карбонил]-1н-пиррол-1-гептановой кислоты (аторвастатин)
HRP960312B1 (en)	1995-07-17	2001-10-31	Warner Lambert Co	NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R, R)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
US6087511A (en) *	1996-07-16	2000-07-11	Warner-Lambert Company	Process for the production of amorphous [R-(R,R)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
US6065729A (en) *	1998-01-28	2000-05-23	Prince Corporation	Slide-out container holder
US5959156A (en)	1998-11-12	1999-09-28	Bp Amoco Corporation	Preparation of polyoxymethylene dimethyl ethers by catalytic conversion of dimethyl ether with formaldehyde formed by oxy-dehydrogenation of dimethyl ether
IN191236B (fr) *	1999-05-25	2003-10-11	Ranbaxy Lab Ltd
HU226640B1 (en) *	1999-10-18	2009-05-28	Egis Gyogyszergyar Nyilvanosan	Process for producing amorphous atorvastatin calcium salt
CZ20021642A3 (cs) *	1999-11-17	2003-05-14	Teva Pharmaceutical Industries Ltd.	Polymorfní formy atorvastatinu vápenatého
US7411075B1 (en) *	2000-11-16	2008-08-12	Teva Pharmaceutical Industries Ltd.	Polymorphic form of atorvastatin calcium
SI20425A (sl) *	1999-12-10	2001-06-30	LEK tovarna farmacevtskih in kemi�nih izdelkov d.d.	Priprava amorfnega atorvastatina
ATE309985T1 (de)	1999-12-17	2005-12-15	Pfizer Science & Tech Ltd	Herstellungsverfahren auf industrieller basis von atorvastatin trihydrat hemi-kalziumsalz in kristalliner form
JP2003517039A (ja) *	1999-12-17	2003-05-20	ワーナー・ランバート・リサーチ・アンド・ディベロップメント・アイルランド・リミテッド	結晶質アトルバスタチンカルシウムの製造方法
PL362472A1 (en) *	2000-11-03	2004-11-02	Teva Pharma	Atorvastatin hemi-calcium form vii
EP1341785B1 (fr) *	2000-11-16	2008-10-08	Teva Pharmaceutical Industries Ltd.	Hydrolyse d'esters d'acide r(r,r)-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- [(phenylamino)carbonyl]-1h-pyrrole-1-heptanoique au moyen d'hydroxyde de calcium
IL156055A0 (en) *	2000-11-30	2003-12-23	Teva Pharma	Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) *	2000-11-30	2009-03-10	Teva Pharaceutical Industries Ltd.	Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US7538136B2 (en) *	2000-12-27	2009-05-26	Teva Pharmaceutical Industries Ltd.	Crystalline forms of atorvastatin
US6476235B2 (en)	2001-01-09	2002-11-05	Warner-Lambert Company	Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
WO2002057228A1 (fr)	2001-01-17	2002-07-25	Biocon India Limited	Atorvastatine calcique
WO2002057229A1 (fr)	2001-01-19	2002-07-25	Biocon India Limited	FORME V CRISTALLINE DE SEL HEMICALCIQUE D'ACIDE [R-(R,R)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIQUE (ATORVASTATINE)
SI20814A (sl)	2001-01-23	2002-08-31	LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.	Priprava amorfnega atorvastatina
SI20848A (sl) *	2001-03-14	2002-10-31	Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D.	Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
IN190564B (fr)	2001-04-11	2003-08-09	Cadila Heathcare Ltd
KR100609371B1 (ko)	2001-06-29	2006-08-08	워너-램버트 캄파니 엘엘씨	Ｒ-(ｒ,ｒ)-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-페닐아미노)카르보닐-1ｈ-피롤-1-헵탄산 칼슘염 (2:1) (아토르바스타틴)의 결정질 형태
BR0211488A (pt)	2001-07-30	2004-08-17	Reddys Lab Ltd Dr	Formas cristalinas vi e vii de atorvastina cálcica
US7074818B2 (en) *	2001-07-30	2006-07-11	Dr. Reddy's Laboratories Limited	Crystalline forms VI and VII of Atorvastatin calcium
JP4188826B2 (ja) *	2001-08-16	2008-12-03	テバファーマシューティカルインダストリーズリミティド	カルシウム塩型スタチンの製造方法
US7563911B2 (en)	2001-08-31	2009-07-21	Morepen Laboratories Ltd.	Process for the preparation of amorphous atorvastin calcium salt (2:1)
JP2005536235A (ja)	2001-11-30	2005-12-02	ユニバーシティオブメリーランド，ボルチモア	腸凝集性大腸菌（ｅａｅｃ）感染の診断および治療に有用なｅａｅｃにおける新規タンパク質
UA77990C2 (en)	2001-12-12	2007-02-15		Crystalline calcium salt of (2:1) [r-(r,r)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
CN100406436C (zh)	2002-02-15	2008-07-30	特瓦制药工业有限公司	阿托韦兹他汀半钙结晶以及制备阿托韦兹他汀半钙形式ix的方法
CA2475123A1 (fr)	2002-02-19	2003-08-28	Teva Pharmaceutical Industries Ltd.	Processus destines a la desolvation des solvates de demi-calcium d'atorvastatine et demi-calcium d'atorvastatine sensiblement exempt de solvant organique
WO2003083638A2 (fr)	2002-03-28	2003-10-09	Emc Corporation	Systeme de stockage de donnees
AU2002356423A1 (en) *	2002-05-28	2003-12-12	Cadila Healthcare Limited	Process for the preparation of amorphous atorvastatin calcium
AU2002330735A1 (en)	2002-09-03	2004-03-29	Morepen Laboratories Limited	Atorvastatin calcium form vi or hydrates thereof
SI21302A (sl)	2002-10-11	2004-04-30	LEK farmacevtska dru�ba d.d.	Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
EP1572643A2 (fr)	2002-11-28	2005-09-14	Teva Pharmaceutical Industries Ltd.	Forme cristalline du sel hemi calcique de l'atorvastatine
EP1424324A1 (fr)	2002-11-28	2004-06-02	Teva Pharmaceutical Industries Limited	Forme cristalline F de calcium d'atorvastatine
US20040242670A1 (en) *	2003-06-02	2004-12-02	Sonny Sebastian	Process for preparation of amorphous atorvastatin calcium
DE202005020766U1 (de) *	2004-07-22	2006-10-05	Teva Pharmaceutical Industries Ltd.	Neue Kristallformen von Atorvastatin-Hemi-Calcium
TW200942516A (en) *	2004-10-18	2009-10-16	Teva Pharma	Processes for preparing amorphous atorvastatin hemi-calcium
US20070032665A1 (en) *	2005-08-04	2007-02-08	Srinivasulu Gudipati	Preparation of atorvastatin calcium form i

2001
- 2001-10-29 IL IL15605501A patent/IL156055A0/xx unknown
- 2001-11-29 CA CA002429590A patent/CA2429590C/fr not_active Expired - Fee Related
- 2001-11-29 EP EP10151205.1A patent/EP2192112B1/fr not_active Expired - Lifetime
- 2001-11-29 KR KR1020037007298A patent/KR100765871B1/ko not_active Expired - Fee Related
- 2001-11-29 MX MXPA03004844A patent/MXPA03004844A/es active IP Right Grant
- 2001-11-29 CN CNA018223400A patent/CN1489463A/zh active Pending
- 2001-11-29 HR HRP20130545AA patent/HRP20130545A2/hr not_active Application Discontinuation
- 2001-11-29 HR HR20030523A patent/HRP20030523A2/hr not_active Application Discontinuation
- 2001-11-29 CA CA002625277A patent/CA2625277A1/fr not_active Abandoned
- 2001-11-29 EP EP01998348A patent/EP1363621A4/fr not_active Ceased
- 2001-11-29 JP JP2002545702A patent/JP2004514694A/ja active Pending
- 2001-11-29 PL PL01363228A patent/PL363228A1/xx not_active Application Discontinuation
- 2001-11-29 SK SK806-2003A patent/SK8062003A3/sk unknown
- 2001-11-29 HU HU0600538A patent/HUP0600538A3/hu unknown
- 2001-11-29 CZ CZ20031766A patent/CZ20031766A3/cs unknown
- 2001-11-29 DE DE0001363621T patent/DE01998348T1/de active Pending
- 2001-11-29 ES ES10151205.1T patent/ES2437157T3/es not_active Expired - Lifetime
- 2001-11-29 WO PCT/US2001/044636 patent/WO2002043732A1/fr not_active Ceased
- 2001-11-29 EP EP10151206A patent/EP2194041A1/fr not_active Withdrawn
- 2001-11-29 EP EP06024449A patent/EP1783113A3/fr not_active Ceased
- 2001-11-29 US US09/997,126 patent/US20020183378A1/en not_active Abandoned
- 2001-11-29 TR TR2004/00815T patent/TR200400815T3/xx unknown
- 2001-11-29 EP EP10152443A patent/EP2192113A1/fr not_active Withdrawn
- 2001-11-29 ES ES01998348T patent/ES2215495T1/es active Pending
- 2001-11-29 CA CA2689915A patent/CA2689915A1/fr not_active Abandoned
- 2001-11-29 BR BR0115892-9A patent/BR0115892A/pt not_active IP Right Cessation
- 2001-11-29 AU AU2002217927A patent/AU2002217927A1/en not_active Abandoned
- 2001-11-29 YU YU42803A patent/YU42803A/sh unknown
2003
- 2003-05-21 IL IL156055A patent/IL156055A/en not_active IP Right Cessation
- 2003-05-27 IS IS6829A patent/IS6829A/is unknown
- 2003-05-28 NO NO20032425A patent/NO20032425L/no not_active Application Discontinuation
- 2003-05-29 BG BG107856A patent/BG107856A/xx unknown
2004
- 2004-07-28 US US10/901,845 patent/US6992194B2/en not_active Expired - Fee Related
- 2004-11-19 US US10/994,142 patent/US7144916B2/en not_active Expired - Fee Related
2005
- 2005-07-29 US US11/192,707 patent/US7151183B2/en not_active Expired - Fee Related
- 2005-07-29 US US11/193,112 patent/US7189861B2/en not_active Expired - Fee Related
- 2005-07-29 US US11/192,672 patent/US7161012B2/en not_active Expired - Fee Related
- 2005-07-29 US US11/193,089 patent/US7256212B2/en not_active Expired - Fee Related
- 2005-07-29 US US11/192,674 patent/US7456297B2/en not_active Expired - Fee Related
- 2005-10-24 US US11/257,828 patent/US7488750B2/en not_active Expired - Fee Related
- 2005-10-24 US US11/257,808 patent/US20060106231A1/en not_active Abandoned
- 2005-10-24 US US11/257,821 patent/US7342120B2/en not_active Expired - Fee Related
- 2005-10-24 US US11/257,815 patent/US20060106232A1/en not_active Abandoned
- 2005-10-24 US US11/257,886 patent/US20060100267A1/en not_active Abandoned
- 2005-10-24 US US11/257,979 patent/US7468444B2/en not_active Expired - Fee Related
2007
- 2007-10-23 US US11/977,387 patent/US20080214650A1/en not_active Abandoned
2009
- 2009-03-11 JP JP2009058477A patent/JP2009120624A/ja active Pending

Also Published As

Publication number	Publication date
EP1783113A3 (fr)	2007-05-30
JP2009120624A (ja)	2009-06-04
US7488750B2 (en)	2009-02-10
CA2625277A1 (fr)	2002-06-06
ES2215495T1 (es)	2004-10-16
KR20030059297A (ko)	2003-07-07
EP1363621A4 (fr)	2005-12-28
HUP0600538A2 (en)	2006-09-28
EP1783113A2 (fr)	2007-05-09
US20050004206A1 (en)	2005-01-06
US7189861B2 (en)	2007-03-13
US7161012B2 (en)	2007-01-09
US20060106232A1 (en)	2006-05-18
SK8062003A3 (en)	2004-07-07
TR200400815T3 (tr)	2004-07-21
IL156055A0 (en)	2003-12-23
PL363228A1 (en)	2004-11-15
US20060100445A1 (en)	2006-05-11
KR100765871B1 (ko)	2007-10-11
ES2437157T3 (es)	2014-01-09
US7468444B2 (en)	2008-12-23
HRP20130545A2 (hr)	2013-11-08
WO2002043732A1 (fr)	2002-06-06
EP2192112B1 (fr)	2013-08-28
US7256212B2 (en)	2007-08-14
US20050261360A1 (en)	2005-11-24
US20050267198A1 (en)	2005-12-01
EP2192112A1 (fr)	2010-06-02
CN1489463A (zh)	2004-04-14
CA2689915A1 (fr)	2002-06-06
HUP0600538A3 (en)	2010-09-28
US7144916B2 (en)	2006-12-05
US20080214650A1 (en)	2008-09-04
US20060100267A1 (en)	2006-05-11
CA2429590A1 (fr)	2002-06-06
NO20032425D0 (no)	2003-05-28
US20050261361A1 (en)	2005-11-24
CZ20031766A3 (cs)	2004-08-18
DE01998348T1 (de)	2004-08-26
US20050090542A1 (en)	2005-04-28
IL156055A (en)	2010-12-30
CA2429590C (fr)	2008-06-10
EP2192113A1 (fr)	2010-06-02
MXPA03004844A (es)	2005-04-19
BG107856A (en)	2004-11-30
EP1363621A1 (fr)	2003-11-26
EP2194041A1 (fr)	2010-06-09
YU42803A (sh)	2006-05-25
US20060058533A1 (en)	2006-03-16
IS6829A (is)	2003-05-27
US20060106231A1 (en)	2006-05-18
US20050261359A1 (en)	2005-11-24
US7456297B2 (en)	2008-11-25
NO20032425L (no)	2003-07-25
US20020183378A1 (en)	2002-12-05
US7342120B2 (en)	2008-03-11
US6992194B2 (en)	2006-01-31
US20060100446A1 (en)	2006-05-11
US7151183B2 (en)	2006-12-19
US20050282885A1 (en)	2005-12-22
BR0115892A (pt)	2003-10-28
HRP20030523A2 (en)	2005-06-30
JP2004514694A (ja)	2004-05-20

Publication	Publication Date	Title
US7468444B2 (en)	2008-12-23	Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US20090143459A1 (en)	2009-06-04	Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
WO2007133597A9 (fr)	2008-01-24	Forme cristalline de calcium d'atorvastatine stable après conservation
US20060020137A1 (en)	2006-01-26	Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
AU2007205725A1 (en)	2007-08-30	Novel cyrstal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
ZA200303976B (en)	2004-11-22	Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms.
MX2008000375A (en)	2008-10-03	Crystalline form of atorvastatin calcium stable after storage

Legal Events

Date	Code	Title	Description
2007-09-06	MK5	Application lapsed section 142(2)(e) - patent request and compl. specification not accepted